Drugs / TD-6450
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02116543 | May → Oct 2014 | hepatitis C virus infection | Theravance Biopharma | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT02716428 | May 2016 → Sep 2017 | chronic hepatitis C virus infection | Trek Therapeutics, PBC | Completed | No outcome recorded |
| Phase 2 | NCT02593162 | Oct 2015 → Dec 2016 | chronic hepatitis C virus infection | Trek Therapeutics, PBC | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT02022306 Comparator | Feb → Aug 2014 | hepatitis C virus infection | Theravance Biopharma | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TD-6450 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02116543 ↗ |
| Action | Inhibit | “orally-administered NS5A hepatitis C virus inhibitor” PMID 37029122 ↗ Apr 2023 |
| Route | Oral | “orally-administered” PMID 37029122 ↗ Apr 2023 |